Safety and Effectiveness of Ticagrelor in Patients Undergoing Carotid Stenting

NCT ID: NCT04091074

Last Updated: 2021-03-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1

Total Enrollment

26 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-01-01

Study Completion Date

2022-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

patients undergoing carotid stenting take dual anti platelet therapy to prevent thrombotic complications usually used drugs are aspirin plus clopidogrel but there are patients not respond so ticagrelor may be an effective and safe alternative

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Carotid Stenosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

aspirin + ticagrelor before carotid stenting

patients undergoing carotid stenting take aspirin 150 mg + ticagrelor 90mg for 15 days before carotid stenting

Group Type ACTIVE_COMPARATOR

Ticagrelor

Intervention Type DRUG

Half of patients undergoing carotid stenting take ticagrelor+aspirin

Carotid stenting

Intervention Type PROCEDURE

Patients with carotid stenosis will undergo carotid stenting

aspirin + clopidogrel before carotid stenting

patients undergoing carotid stenting take aspirin 150 mg + clopidogrel 75 mg for 15 days before carotid stenting

Group Type ACTIVE_COMPARATOR

Clopidogrel

Intervention Type DRUG

Other half ofpatients undergoing carotid stenting take clopidogrel+aspirin

Carotid stenting

Intervention Type PROCEDURE

Patients with carotid stenosis will undergo carotid stenting

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ticagrelor

Half of patients undergoing carotid stenting take ticagrelor+aspirin

Intervention Type DRUG

Clopidogrel

Other half ofpatients undergoing carotid stenting take clopidogrel+aspirin

Intervention Type DRUG

Carotid stenting

Patients with carotid stenosis will undergo carotid stenting

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Ischemis stroke of both sex.
2. More than 18 years.
3. Accepting all study requirements.

Exclusion Criteria

1. Refuse to comply with all study requirements.
2. bleeding tendency or liver diseases
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assiut University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Osama Ibrahim Aboelfath Ibrahim

Osama Ibrahim Aboelfath Ibrahim

Responsibility Role PRINCIPAL_INVESTIGATOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Ticagrelor in carotid stenting

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.